Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Sees Large Growth in Short Interest

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) was the recipient of a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 145,500 shares, an increase of 63.3% from the October 31st total of 89,100 shares. Approximately 2.7% of the company’s shares are sold short. Based on an average trading volume of 340,600 shares, the short-interest ratio is presently 0.4 days.

Protagenic Therapeutics Trading Down 18.1 %

PTIX stock opened at $0.60 on Friday. Protagenic Therapeutics has a 1-year low of $0.49 and a 1-year high of $1.87. The stock has a 50-day moving average price of $0.62 and a 200-day moving average price of $0.80. The firm has a market cap of $4.06 million, a PE ratio of -0.47 and a beta of 0.24.

Protagenic Therapeutics Company Profile

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.